Advisor Group’s BioCryst Pharmaceuticals BCRX Stock Holding History

Advisor Group’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$0	Hold	50	–	–	﹤0.01%	5300
2019 Q3	$0	Hold	50	–	–	﹤0.01%	5264
2019 Q2	$0	Hold	50	–	–	﹤0.01%	5221
2019 Q1	$0	Hold	50	–	–	﹤0.01%	5204
2018 Q4	$0	Hold	50	–	–	﹤0.01%	5099
2018 Q3	$0	Sell	50 -200	-80%	-$1.34K	﹤0.01%	5097
2018 Q2	$1K	Hold	250	–	–	﹤0.01%	4771
2018 Q1	$1K	Sell	250 -200	-44%	-$1.03K	﹤0.01%	4791
2017 Q4	$2K	Buy	+450	New	+$2.18K	﹤0.01%	4662
2017 Q1	–	Sell	-1,000	Closed	-$6K	–	4683
2016 Q4	$6K	Sell	1,000 -1,000	-50%	-$5.2K	﹤0.01%	3828
2016 Q3	$9K	Hold	2,000	–	–	﹤0.01%	3600
2016 Q2	$5K	Buy	+2,000	New	+$6.21K	﹤0.01%	3765

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Advisor Group's BCRX Position: Q4 2019 in Review

Advisor Group held its BioCryst Pharmaceuticals (BCRX) position steady in Q4 2019 at 50 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #5300.

Advisor Group first reported a position in BCRX in Q2 2016 and has held it in 12 quarters since. The position peaked at $9K in Q3 2016. 136 funds tracked by Wall St. Rank hold BCRX as of Q4 2019.

Advisor Group held 50 shares of BioCryst Pharmaceuticals worth $0 as of Q4 2019.
Advisor Group left its BioCryst Pharmaceuticals share count unchanged in Q4 2019.
BioCryst Pharmaceuticals made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #5300 holding.
Advisor Group first reported a position in BioCryst Pharmaceuticals in Q2 2016 and has held it in 12 quarters since.
Advisor Group's BioCryst Pharmaceuticals position peaked at $9K in Q3 2016.
136 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.